Status:
COMPLETED
Additive Homeopathy in Cancer Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
Malignant Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patien...
Detailed Description
The EORTC-QLQ-C30, SF-36 as well as a VAS scale for subjective well-being will be filled out by the patients.
Eligibility Criteria
Inclusion
- Informed consent
- Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.
Exclusion
- sensitizing mutation of the EGFR gene or translocation of the ALK gene
- refusal to sign informed consent
- pregnancy
- hematological, hepatic, or renal pathology
- coronary heart disease
- history of secondary tumor
- major surgery within 4 weeks prior to study entry
- active infection and symptomatic peripheral neuropathy
- central nervous system metastases unless the metastases were treated and stable
- active autoimmune disease
- use of systemic immunosuppressive treatment
- use of systemic treatment during the previous 2 years
- active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed
- previous systemic therapy for metastatic disease or previous irradiation
- use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01509612
Start Date
February 1 2012
End Date
July 31 2019
Last Update
June 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Michael Frass
Vienna, Austria, 1120